Comprehensive Analysis of EGFR Signaling Pathways in Japanese Patients With Non-Small Cell Lung Cancer

Lung Cancer - Netherlands
doi 10.1016/j.lungcan.2009.01.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients With EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P108 Distribution Characteristics and Response Analysis of Non-Small Cell Lung Cancer Patients With EGFR Rare Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

Dual Inhibition of EGFR and mTOR Pathways in Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy